NU7441 Will Show You Advanced Lingo : : We Move Directly Into The Project

5; P?=?0.528) were comparable between the two groups. No significant treatment difference was observed with respect to number of moderate/severe COPD exacerbations per year (Glycopyrronium?=?0.38 versus tiotropium?=?0.35 [95% CI: 0.62???1.93]; P?=?0.754). Overall, incidence of adverse events was similar in the glycopyrronium (40.4%) and tiotropium (40.6%) groups. Conclusion?Glycopyrronium and tiotropium showed similar effective and sustained bronchodilation with similar impact on dyspnea, health status, exacerbations rate, rescue medication use, safety and tolerability. Glycopyrronium's onset of bronchodilation was significantly more rapid following the first dose. 1.?Kerwin, E, et?al. Eur Resp J 2012;40:1106�C1114. Oxygenase KENNETH R CHAPMAN1, ERIC D BATEMAN2, NICOLA GALLAGHER3, HUILIN HU4, HAN-JO KIM4, DONALD BANERJI4 1Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Canada, 2Department of Medicine, University of Cape Town, Cape Town, South Africa, 3Novartis Horsham Research Centre, West BKM120 in vitro Sussex, UK, 4Novartis Pharmaceuticals Corporation, East Hanover, USA Introduction?The current GOLD strategy recommends combining two long-acting bronchodilators for the maintenance treatment of patients with moderate-to-severe COPD. The SHINE study evaluated the effect of QVA149, a dual bronchodilator combining the LABA indacaterol and the LAMA glycopyrronium (NVA237), compared with glycopyrronium, indacaterol, tiotropium monotherapies and placebo. Methods?In this 26-week, multicenter, double-blind, parallel-group, placebo and active controlled (open-label tiotropium) study, patients ��40 years with moderate-to-severe COPD (post-bronchodilator FEV1/FVC?NU7441 (150?��g), glycopyrronium (50?��g), tiotropium (18?��g) or placebo (2?:?2?:?2?:?2?:?1). Here, we present the improvements in lung function, Transition Dyspnea Index (TDI) and St. George's Respiratory Questionnaire (SGRQ) total score by COPD disease severity and prior medication use. Results?In total, 2144 patients (mean age 63.9 years; mean FEV1 post-bronchodilator 55.2% predicted) were randomized (QVA149 [n?=?475]; indacaterol [n?=?477]; glycopyrronium [n?=?475]; tiotropium [n?=?483]; placebo [n?=?234]); 89.1% completed the study. Significant improvements in lung function, dyspnea and health status were observed with QVA149 compared to placebo with a treatment difference of 370?mL and 260?mL in FEV1 AUC5min�C4h, 240 and 120?mL in trough FEV1, 1.17 and 1.00 in TDI and ?2.74 and ?3.77 in SGRQ score, in patients with moderate and severe COPD, respectively. Compared with placebo, QVA149 demonstrated a significant improvement in lung function, dyspnea and health status with a treatment difference ranging from 300 to 370?mL for FEV1 AUC5min�C4h and 170 to 250?mL for trough FEV1, 0.71 to 2.27 in TDI and ?0.34 to ?5.